Abstract
The discovery of drugs is a lengthy, high-risk and expensive business taking at least 12 years and is estimated to cost upwards of US$800 million for each drug to be successfully approved for clinical use. Much of this cost is driven by the late phase clinical trials and therefore the ability to terminate early those projects destined to fail is paramount to prevent unwanted costs and wasted effort. Although neglected diseases drug discovery is driven more by unmet medical need rather than financial considerations, the need to minimise wasted money and resources is even more vital in this under- funded area. To ensure any drug discovery project is addressing the requirements of the patients and health care providers and delivering a benefit over existing therapies, the ideal attributes of a novel drug needs to be pre-defined by a set of criteria called a target product profile. Using a target product profile the drug discovery process, clinical study design, and compound characteristics can be defined all the way back through to the suitability or druggability of the intended biochemical target. Assessment and prioritisation of the most promising targets for entry into screening programmes is crucial for maximising chances of success.
Keywords: Chemical validation, druggability, drug resistance, genetic validation, neglected diseases, molecular targets, target assessment, target product profile, discovery of drugs, paramount, vital, biochemical target, vector-borne parasitic diseases, African sleeping sickness, molecular target approach
Current Topics in Medicinal Chemistry
Title: Target Validation: Linking Target and Chemical Properties to Desired Product Profile
Volume: 11 Issue: 10
Author(s): Paul G. Wyatt, Ian H. Gilbert, Kevin D. Read and Alan H. Fairlamb
Affiliation:
Keywords: Chemical validation, druggability, drug resistance, genetic validation, neglected diseases, molecular targets, target assessment, target product profile, discovery of drugs, paramount, vital, biochemical target, vector-borne parasitic diseases, African sleeping sickness, molecular target approach
Abstract: The discovery of drugs is a lengthy, high-risk and expensive business taking at least 12 years and is estimated to cost upwards of US$800 million for each drug to be successfully approved for clinical use. Much of this cost is driven by the late phase clinical trials and therefore the ability to terminate early those projects destined to fail is paramount to prevent unwanted costs and wasted effort. Although neglected diseases drug discovery is driven more by unmet medical need rather than financial considerations, the need to minimise wasted money and resources is even more vital in this under- funded area. To ensure any drug discovery project is addressing the requirements of the patients and health care providers and delivering a benefit over existing therapies, the ideal attributes of a novel drug needs to be pre-defined by a set of criteria called a target product profile. Using a target product profile the drug discovery process, clinical study design, and compound characteristics can be defined all the way back through to the suitability or druggability of the intended biochemical target. Assessment and prioritisation of the most promising targets for entry into screening programmes is crucial for maximising chances of success.
Export Options
About this article
Cite this article as:
G. Wyatt Paul, H. Gilbert Ian, D. Read Kevin and H. Fairlamb Alan, Target Validation: Linking Target and Chemical Properties to Desired Product Profile, Current Topics in Medicinal Chemistry 2011; 11 (10) . https://dx.doi.org/10.2174/156802611795429185
DOI https://dx.doi.org/10.2174/156802611795429185 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
N-Containing Ag(I) and Hg(II) Complexes: A New Class of Antibiotics
Current Topics in Medicinal Chemistry Effective Delivery Routes and Strategies for Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC)
Current Pharmaceutical Design Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Effects of Edible Algae Polysaccharides on Allergic, Inflammatory, and Anti-Tumor Responses Through Toll-Like Receptor 4
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 4-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)phenyl)-1-((5-amino-1,3,4-thiadiazol-2-yl)methyl)-3-benzyl-1H-1,2,4-triazol-5(4H)-one: Synthesis, Characterization and Computational Studies
Letters in Organic Chemistry Structure-based Drug Design Targeting Biosynthesis of Isoprenoids: A Crystallographic State of the Art of the Involved Enzymes
Current Protein & Peptide Science In Silico Assessment of Adverse Effects of a Large Set of 6-Fluoroquinolones Obtained from a Study of Tuberculosis Chemotherapy
Current Drug Safety The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Fullerenes for Cancer Diagnosis and Therapy: Preparation, Biological and Clinical Perspectives
Current Drug Metabolism Nitroimidazole Radiopharmaceuticals in Bioimaging: Part I: Synthesis and Imaging Applications
Current Radiopharmaceuticals <i>Enoyl-Acyl Carrier Protein Reductase (INHA)</i>: A Remarkable Target to Exterminate Tuberculosis
Anti-Infective Agents Preclinical Models of Multiple Sclerosis: Advantages and Limitations Towards Better Therapies
Current Medicinal Chemistry Antimicrobial Evaluation of Some Arylsulfanylpyrazinecarboxylic Acid Derivatives
Medicinal Chemistry New Antimycobacterial Leads from Multicomponent Hydrazino-Ugi Reaction
Medicinal Chemistry Targeting Bacterial RNA Polymerase: Promises for Future Antisense Antibiotics Development
Infectious Disorders - Drug Targets Patent Selections
Recent Patents on Anti-Infective Drug Discovery Drug Metabolizing Enzymes and Transporters mRNA in Peripheral Blood Mononuclear Cells of Healthy Subjects: Biological Variations and Importance of Preanalytical Steps
Current Drug Metabolism Bactericidal and Hemolytic Activities of Synthetic Peptides Derived from Granulysin
Protein & Peptide Letters Design of multifunctional nanocarriers for delivery of anti-cancer therapy
Current Pharmaceutical Design Magnetic Digital Microfluidics for Point-of-Care Testing: Where Are We Now?
Current Medicinal Chemistry